Active Clinical Trials

Active Thyroid Cancer Specific Trials

For available solid tumor basket trials please e-mail us at or call 310-222-8172.


1) Validation of the DDMS Diagnostics in Thyroid Fine Needle Aspirations (link not available)

2) Adolescents and Young Adults with Cancer: Race, Ethnicity and Treatment Site (link not available)

3) The Role of Thyroid Hormones in Breast Tumorigenesis (link not available)

4) Clinical Outcome of Anaplastic Thyroid Carcinoma at City of Hope, 10- Years Retrospective Study (link not available)

5) Identification of Novel Biomarkers in Head and Neck Cancers Through Retrospective Analysis of Biorepository Tissues (link not available)

6) Epigenetic Biomarker Development for Thyroid Nodule Diagnostics (link not available)

7) Comparison of the Diagnostic Accuracy in One-Needle Fine Needle Aspiration (FNA) Plus Biopsy to Conventional FNA Alone and to Conventional Biopsy Alone (link not available)

8) Development Molecular Diagnostics for Thyroid Cancer (link not available)

9) Analysis of Different Cell Populations in Benign and Malignant Thyroid Tissues (link not available)

10) Development of Thyroid Cancer Diagnostics by Using Prospective Tissue Collection (link not available)

11) A Retrospective Analysis of BRAF Mutation Status and Clinicopathologic Characteristics in Various Solid Tumors (link not available)

12) Retrospective-Prospective Collection of Thyroid Specimens After FNA (link not available)

13) A phase 1/2 study of TPX-0046, a novel oral RET/SRC inhibitor in adult subjects with advanced/metastatic solid tumors harboring oncogenic RET fusions or mutations.

14) A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid Tumors

15) A Phase 3 Trial Comparing Loxo-292 to Physicians Choice of Cabozantinib or Vandetanib in Patients with Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)

16) Phase II Study of XL184 (Cabozantinib) in Combination with Nivolumab and Ipilimumab (CaboNivoIpi) in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Whose Cancer Progressed After One Prior VEGFR-Targeted Therapy

17) Phase 1/2 Study of LOXO-292 in Patients with Advanced Solid Tumors, RET Fusion-positive Solid Tumors, and Medullary Thyroid Cancer

18) Phase II Clinical Trial for Tipifarnib for HRAS-mutant Thyroid Cancer

19) Active Surveillance of Papillary Thyroid Microcarcinoma

20) Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers (Enrollment closed)

21) A Study of Cabozantinib Compared with Placebo in Subjects with Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-targeted Therapy (Enrollment closed)